Multiple vertebral fractures after suspension of denosumab. A series of 56 cases
{{output}}
Background: Denosumab is a monoclonal antibody approved for the treatment of postmenopausal osteoporosis. The withdrawal of denosumab produces an abrupt loss of bone mineral density and may cause multiple vertebral fractures (MVF... ...
